Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
swazer
It was a reasonable speculation on the basis that PHE had not yet confirmed anything. And I half expected another rant from you. Remember the one timed at 00.18h a week or two back that you deleted, when I pointed out that post midnight rants are rarely helpful? And now you are at it in the daytime as well. If you have anger issues there are folk who might be able to help you. I am not alone on this board in finding your posts unpleasant. Please go away and stay away in the absence of any useful contribution.
Jelenko
I do not understand you. Parsortix does not 'capture' cDNA, that is, tumour DNA fragments in plasma. Period. in order to extract and use cDNA from plasma is a highly complex process being used and refined by several American companies. Parsortix can capture CTCs by a clever microfluidic process. i accept that the plasma from a single blood sample used for Parsortix could also be used to search for cDNA, but capturing TCs and extracting cDNA from plasma are entirely separate processes. AGL per se is not in the business of extracting cDNA.
What I was trying to get at is whether there is enough information available from cDNA for clinical decisions to be made reliably and reproduceably. This is what the present Marsden study seeks to determine.
Please tell us what research you relied on to make the statement "Parsortix captures CtDNA if required"
The basic question for me is: what advantages does the capture of CTCs over circulating DNA (cDNA) ? How reliable is extraction of cDNA, and how consistently can one detect it in blood of patients with residual tumour (which is what the study from the Marsden is about). If it provides enough info for an informed treatment decision to be made, and cDNA can be extracted more consistently than capture of CTCs, then AGL is in deep trouble.
Parsortix is the Roll-Royce of tumour cell analysis, but if capture rates are significantly lower than rates for extraction of cDNA, or if enough info can be consistently extracted from cDNA then a Rolls may be redundant. As an LTH, I hope not, but am far from happy with the present state of AGL
In the Newsletter I don't think he meant 'where it can pull a big punch'; sounds good but means the opposite to what he intended! It means to strike a blow less powerful or forceful than it could be. Oh dear.
Dibs
As an LTH, I wish I could share your confidence. I just have a feeling Angle has missed the boat with Parsortix. Otherwise clinicians would be falling over themselves to use the technology, and that seems not to be the case. T/O, if anyone really wants the technology, might have to be the solution. Sorry to be gloomy!
AN is now neither an engineer or a scientist but has, after university where he read engineering, a background in finance if I remember his interview last year. Anyway, one way or the other this is way oversold